Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocin Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Enveric Biosciences
Deal Size : $62.0 million
Deal Type : Licensing Agreement
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Details : MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders such as depression.
Brand Name : EB-002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 12, 2024
Lead Product(s) : Psilocin Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Enveric Biosciences
Deal Size : $62.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Psilocybine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Obvious Ventures
Deal Size : $60.0 million
Deal Type : Financing
Details : The proceeds from the financing will be used to advance the company’s next stage of operations having psilocybine on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Obvious Ventures
Deal Size : $60.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?